Emmes is excited to share the significant progress being made in clinical studies.
We also give you a look inside some of our own news.
Emmes Announces FDA Clearance of New Medical Device
Company News
<p>The New "Mercy TAPE" Estimates Pediatric Weight with Greater Accuracy, Giving Doctors a Better Tool for Determining Prescription Dosage.<br />
The Emmes Corporation today announced that the U.S. Food and Drug Administration (FDA) has given marketing clearance for a new device that allows doctors to more accurately assess children’s weight without the use of a weight scale. Weight estimates are used in emergency situations and in developing countries where scales may not be available. This new device will allow doctors to determine with greater accuracy the prescription dosage levels needed for children with a range of illnesses and across a variety of settings throughout the world.</p>
EMMES to Coordinate NCI Anal Cancer Prevention Study
Company News
<p>With the support of The EMMES Corporation, clinical investigators from the AIDS Malignancy Consortium (AMC) are preparing to enroll HIV-infected men and women throughout the United States and Puerto Rico in a major investigation of a prevention strategy for anal cancer. The study will enroll over 5,000 participants who are HIV-infected and who have pre-cancerous lesions. EMMES will provide operations, data management, site monitoring, and regulatory support under the eight-year, $89 million award. The study is scheduled to begin enrollment this month.</p>
EMMES Wins IDIQ Contract
Company News
<p>Under the contract, EMMES will provide a full range of services that support public health emergency preparedness. These include statistical expertise and project management, study design and protocol development, data collection, and data analysis and reporting. In addition, the company will also provide enhanced safety reporting through its pharmacovigilence program with both Emergency Medicine and Infectious Disease expertise and will manage a large team of subcontractors at laboratories and sites across the country. The two-year contract, which includes three one-year options, has a ceiling of $100 million. EMMES was one of five companies selected to compete for services under this IDIQ contract.</p>
New research firm CEO never stops learning
Company News
<p>When she was young, Anne Lindblad was interested in medicine, even becoming a physician, until she came face-to-face with the inevitable frog to dissect in high school biology class. “I mutilated that frog,” recalled Lindblad, who recently was promoted to CEO and president of The Emmes Corp., a Rockville research company that conducts studies for clinicians and biomedical scientists. “That dashed my hopes of becoming a physician.” But math was another of her likes, and after growing up in Cleveland, Ohio, she enrolled at Hollins University in Roanoke, Va. “It was one of the few colleges in the area that offered a degree in statistics back then,” Lindblad said. After earning a statistics degree there, she went to the Medical College of Virginia in Richmond and obtained a master’s in biostatistics. She started teaching at the all-girls Foxcroft School in Middleburg, Va., where she began a statistics course. While in graduate school, Lindblad met Donald Stablein, who earned a doctorate in biostatistics from the Medical College of Virginia and started working for Emmes as a staff statistician in 1980, some three years after the company formed. Stablein eventually became president of Emmes. “We kept in contact, and he asked me if I wanted a job,” said Lindblad, who earned a doctorate herself in statistics from George Washington University. She joined Emmes in 1982 and worked her way to vice president in 1992 and executive vice president in 2006. She has led major projects in ophthalmology, oncology, transplantation, neurology, stroke, traumatic brain injury and more. “I’m in a field where you never stop learning,” Lindblad said.</p>
EMMES Renews Lease
Company News
<p>The EMMES Corporation today announced that it has signed a 10-year lease that gives the company expanded office space at its current headquarters at 401 North Washington Street in Rockville’s town center. The lease totals 97,000 square feet.<br />“Our new lease signals the next chapter of success for the company,” said Dr. Anne Lindblad, executive vice president of EMMES. “We have built a reputation as a trusted partner to researchers who are dedicated to developing better treatments for patients. We’re proud of our 35-year history, and we’re optimistic about our future opportunities.”<br />Brian Hochheimer, EMMES vice president and chief financial officer, added, “The new lease supports our growth and hiring plans. It gives us four full floors and represents nearly a three-fold expansion compared to the square footage of our original lease. We love being right in the center of Rockville, and we’re pleased to continue the relationship with our landlord, 401 North Washington LLC.”<br />According to Isiah Leggett, Montgomery County executive, “We’re thrilled that EMMES has decided to remain in Rockville, the third largest city in Maryland and a robust business center. EMMES has been a pillar of our local economy, creating and sustaining jobs that contribute to the improvement of public health. The company offers scientific, technology and research services and has a highly educated employee base.”<br />Phyllis Marcuccio, Rockville mayor, noted, "We are delighted that EMMES, one of our major employers, has elected not only to remain in our city, but to enlarge and upgrade its space. The City of Rockville<br />looks forward to working with and supporting the company as it continues to contribute to the life sciences industry cluster here."<br />Leggett added, “With the signing of the new lease, EMMES remains close to the campus of one of its major customers, the National Institutes of Health. Company executives cited the outstanding location in Rockville Town Center, proximity to public transportation and the excellent educational offerings at the Universities at Shady Grove as key reasons for maintaining its headquarters in our county.”<br />EMMES was represented by Larry Bank and Lisa Benjamin of Newmark Grubb Knight Frank in the transaction.</p>
Anne Lindblad Promoted to President/CEO of The EMMES Corporation
Company News
Dr. Lindblad is a biostatistician with experience in clinical design and project management. Lindblad joined EMMES in 1982 and became vice president in 1992 and executive vice president in 2006. During her 30-year career at EMMES, she has led major projects in ophthalmology, oncology, nephrology, transplantation, neurology, stroke, traumatic brain injury, dental disease and swallowing disorders. She has served as a reviewer of grant and contract applications for the National Institutes of Health and has chaired or served on Data and Safety Monitoring Committees in multiple disease areas. In addition, she has served on the board of directors and as president of the Society for Clinical Trials, as well as the clinical trials section editor for JAMA Ophthalmology, formerly the Archives of Ophthalmology. Lindblad has authored or co-authored more than 100 publications and presentations. She holds a Ph.D. in statistics from the George Washington University, a master’s degree in biostatistics from the Medical College of Virginia, and a bachelor’s degree in Statistics from Hollins College. Lindblad lives in Middleburg, Virginia, with her husband and two daughters.
Emmes Launches New Internship Program with an Egyptian Children's Cancer Hospital
Company News
The Emmes Corporation today announced the creation of an internship program in which the company will offer one fellow from Egypt’s Children Cancer Hospital an internship to gain training and experience in clinical research. Under the new program, one fellow will be selected each year to travel to Emmes’ headquarters in Rockville, Maryland, to work with its clinical research experts. The duration of each internship will be determined on a case-by-case basis.
Dr. Anne Lindblad, president and chief executive officer of Emmes, explained that the internship program was a natural extension of the company’s recent education efforts in Egypt. Emmes’ Dr. Ashraf El Fiky and Dr. Robert Lindblad were keynote speakers at the 53rd Alexandria Congress on Allergy and Immunology in Alexandria, Egypt. The conference, scheduled from February 21 to 23, was attended by leading allergy and immunology specialists from Egyptian universities.
Following that conference, El Fiky, Emmes’ clinical trials medical officer for drug safety and pharmacovigilance, and Lindblad, vice president and chief medical officer, traveled to Cairo to speak at an event at the Children Cancer Hospital. They spoke about cancer clinical trials at the First Symposium on Clinical Research in Oncology and Good Clinical Practice Guidelines on February 25.
The Children Cancer Hospital is the largest pediatric oncology hospital in the Middle East. According to El Fiky, “Our new internship program recognizes the hospital’s important role in providing free pediatric oncology services to patients in the region. Its joint fellowship programs with Harvard Medical School, the Dana-Farber Cancer Institute and St. Jude Children’s Research Hospital are great role models. Emmes is truly proud to support the clinical research community in Egypt.”
Two years ago, Emmes had hosted members of the senior management team from Cairo’s Children Cancer Hospital as part of a tour that included the National Institutes of Health and other area biohealth organizations.
“We’re excited to continue to collaborate with Egypt’s medical community and academic institutions and expand our new relationships,” said Dr. Anne Lindblad. “We believe our internship program demonstrates this commitment, and we look forward to hosting our first fellow later this year.”
About Emmes
We collaborate with our clients to produce valued, trusted scientific research. Our team members at Emmes are passionate about making a difference in the quality of human health, and we have supported more than a thousand studies across a diverse range of diseases since our formation in 1977. Our research is contributing to a healthier world. For more information, visit the Emmes website at www.emmes.com.
Data Analysis Conducted by Emmes Contributed to New NIH Research Linking Air Pollution to Preterm Birth Risks in Mothers with Asthma
Company News
The Emmes Corporation today announced that it contributed to a landmark research study by the National Institutes of Health linking air pollution and preterm birth risk in pregnant women with asthma. The study, published in the Journal of Allergy and Clinical Immunology, reported that pregnant women with asthma have an increased risk for preterm birth when exposed to high levels of nitrogen oxides and carbon monoxide, common traffic-related air pollutants.
The study found that exposure to nitrogen oxide, for example, in the three months prior to conception, increased preterm birth risk by nearly 30 percent for women with asthma compared to 8 percent for women without asthma.
The company’s work on this study initially began with a project for the Consortium on Safe Labor, in which an Emmes team conducted statistical analysis on more than 223,000 records of pregnant women. The data, spanning six years, were subsequently merged with air pollution data generated from a modified computational tool called the Community Multi-scale Air Quality Modeling System available from the Environmental Protection Agency. The goal was to determine whether there was a relationship between levels of air pollutants and pregnancy outcomes.
Emmes Names Lynn Lewis Chief Business Officer
Company News
Emmes today announced that Lynn Lewis has joined the company as chief business officer, a newly created position. Her overall focus is to build deeper relationships with existing clients and to develop new business opportunities, particularly among biotech and pharmaceutical companies.
Lewis will be responsible for sales, marketing, communications, strategic planning and partnerships, and proposal development.
Dr. Anne Lindblad, president and chief executive officer of Emmes, said, “Lynn understands the importance of science in our business. She will extend our reputation and value as a trusted scientific partner with those who share our passion for designing and executing important studies aimed at improving human health.”
She added, “Lynn’s experience and accomplishments in sales and marketing complement the capabilities of our executive management team. She has a history of driving the development of new products and services for pharmaceutical companies globally.”
Lewis began her career at Eli Lilly & Company, a leading global pharmaceutical firm based in Indianapolis, Indiana. She held numerous positions in sales, marketing, strategic planning and general management. Her final role there was as project team leader, and she led a global scientific and commercial team to gain U.S. and European approvals for Forteo, an osteoporosis product. She then spent 15 years at Covance Inc., a contract research organization based in Princeton, New Jersey, serving biopharmaceutical companies. There, she started as vice president of global sales, marketing and commercial development for one of its divisions. She was subsequently promoted to positions with increasing sales and marketing responsibilities, including group vice president for business development, clinical development and commercialization services. Before joining Emmes, Lewis was chief commercial officer for Envigo, a contract research organization based in Somerset, New Jersey, serving biopharmaceutical and other life sciences companies. During her 18-month tenure, her team achieved the highest sales level in company history.
“I’m looking forward to building a strong business development team here at Emmes,” said Lewis. “My goal is to develop people and processes that extend the company’s reputation as a government research partner and generate new private sector relationships.”
Lewis has a Master of Business Administration in international business and marketing from the University of North Carolina’s Kenan-Flagler Business School and a Bachelor of Science in biology from Bucknell University. She lives in McCordsville, Indiana.
About Emmes
We collaborate with our clients to produce valued, trusted scientific research. Our team members at Emmes are passionate about making a difference in the quality of human health, and we have supported more than a thousand studies across a diverse range of diseases since our formation in 1977. Our research is contributing to a healthier world. For more information, visit the Emmes website at www.emmes.com.
Emmes Honored for Workplace Excellence
Company News
Emmes today announced that it has received a Workplace Excellence Seal of Approval from Alliance for Workplace Excellence (AWE). This is the fifth consecutive year the company has received the AWE Workplace Excellence award.
The AWE created the annual recognition program to honor organizations that show an exemplary commitment to building excellent places to work in Montgomery County, Maryland, and throughout the United States. Workplace Excellence winners are evaluated on such attributes as innovative corporate culture and management practices, family-friendly policies and programs, employee growth and learning opportunities, and a commitment to corporate responsibility.
Emmes also received a Health & Wellness Seal of Approval from the AWE for innovative programs promoting employee health and wellness. The AWE award considered employee health fairs, support for physical activity and healthy eating programs, health risk assessments, educational programs on healthy lifestyle, and incentives for participation in wellness programs.
In addition to the AWE recognition, Emmes was honored with a Gold Award from the Maryland Department of Health. Its Healthiest Maryland Businesses Wellness at Work Awards program salutes businesses in the state that are committed to improving employee health and well-being.
According to the Maryland Department of Health, Healthiest Maryland Businesses is a collaborative of Maryland businesses with a shared mission of improving health through worksite wellness efforts.
There are three awards – gold, silver and bronze – and Emmes’ Gold Award acknowledged the well-established workplace wellness practices that promote a culture of health at all levels and utilize policy, programming, benefits, and environmental supports to improve employee health.
Dr. Anne Lindblad, president and chief executive officer of Emmes, said, “We are so proud to be honored with both the Workplace Excellence Seal of Approval and the two Health & Wellness awards. Our leadership team continues to listen to what employees want, and we have created and improved programs and activities that enrich our employees’ lives and make us an even better place to build a career.”
Lindblad added, “Our company was founded on a dedication to research that addresses the health needs of people representing all ages and walks of life. The fact that we have been selected for awards relating to health and wellness makes it even more gratifying.”
About Emmes
We collaborate with our clients to produce valued, trusted scientific research. Our team members at Emmes are passionate about making a difference in the quality of human health, and we have supported more than a thousand studies across a diverse range of diseases since our formation in 1977. Our research is contributing to a healthier world. For more information, visit the Emmes website at www.emmes.com.
